Therapy of : What does the future hold?

MICHAEL DAVIDSON M.D. FACC, DIPLOMATE OF THE AMERICAN BOARD OF PROFESSOR , DIRECTOR OF PREVENTIVE CARDIOLOGY THE UNIVERSITY OF CHICAGO PRITZKER SCHOOL OF MEDICINE Severe Refractory HTG: High Unmet Medical Need 2

. 3-5000 with LPL or apoC-II deficiency (orphan indications) . 30-50K with severe refractory HTG (orphan indication approved) . 25% of patients with HTG have apoA-V polymorphisms

1. Patient 1. 2. TG 3700 mg/dL Ch 546 mg/dL Lipemia 2. Healthy retinalis TG 100 mg/dL Ch 200 mg/dL

xanthomas Palmar crease filled with xanthomas foam cells

Yuan G et al. CMAJ 2007;176:1113-1120 metabolism with high and normal hepatic TG production

ApoA5 Very Small LPL Large VLDL LDL ApoB ApoE ApoB TG Production Remnant LDL-C Non-HDL-C Low Renal clearance High TG

HL HDL sHDL CETP

CE TG TG

HL Large LPL LPL/HL Very Remnants Small Small VLDL slow LDL LDL ApoB ApoB ApoC-III ApoB ApoE ApoC-III ApoB ApoE ApoC-III ApoC-III Remnant Cholesterol LDL-C Non-HDL-C Cholesterol Targeted Therapies for Refractory Hypertriglyceridemia with Genotype based Patient Selection 4 Lipase enzyme activity is regulated by

ApoAV peptide ApoCII peptide

CETP

TG Production ApoA5 ApoC2 CE TG TG

LPL LPL/HL HL Very High VLDL Remnants Small Small slow LDL LDL ApoB ApoB ApoC-III ApoB ApoE ApoC-III ApoB ApoE ApoC-III ApoC-III Remnant Cholesterol LDL-C

Non-HDL-C

apoC3 ASO LPL gene therapy

Cholesterol Triglycerides

Confidential 1H2015 Glybera Gene Replacement Therapy for LPL Deficiency

In vivo intramuscular injection AAV1-Capsid Containing the AAV2-LPL s447x cassette

• First Gene replacement therapy being authorized in the occidental world

• Designed for patients with FCS due to loss-of-function LPL gene mutations.

• Not for FCS caused by apoA-5, apoC-2, GPIHPB1, LMF-1 gene mutations.

• Requires genotyping (genetic test) Glybera Mechanism of Action Fasting TG Decreased After 12 Weeks of Treatment but Returned to

Baseline After 5 Months TG (mmol/L) TG

10

2 weeks after injection + 19 w

HISTORICAL VALUES AMT-011-01 and 02 STUDY F-U 3H- Clearance 14 Weeks and One Year After Treatment (fasting TG values at week-52 were back to baseline values)

0.8 wk-2 wk+14 0.7 wk+52

0.6

0.5 before treatment 0.4

0.3 At 52 weeks

CM3H activity(%ID/100 mL) 0.2 At 14 weeks

0.1

0 0 5 10 15 20 25 30 time after test meal (hrs)

Results shown are a mean ± SEM; n=5 (wk-2 and wk+14) or n=3 (wk+52) p-values: t-test AUC24hrs; wk -2 versus wk +14 and wk +52 Risk Reduction of Definite, Probable Pancreatitis and Abdominal Pain Events

10 Years p < 0.001 Consistent 56 - 67% 9 Years p < 0.001 risk reduction 8 Years p < 0.001 7 Years p < 0.001 – p-values 0.001 - 0.007 6 Years p < 0.001

5 Years p < 0.001

4 Years p = 0.001

3 Years p < 0.001

2 Years p = 0.007

1 Year p = 0.019

0 0.2 0.4 0.6 0.8 1.0 1.2

Hazard Ratio with 95 % Confidence Interval

9 ApoC-III inhibits the conversion of VLDL to LDL and causes small dense LDL and low HDL

Small, dense HDL Hypertriglyceridemia Apo A-I HDL ApoC-III

TG CETP CE

ApoC-III

VLDL LDL TG TG VLDL DGAT TG TG TG

CE TG CETP Glycerol Apo B-100 ApoC-III CE

Liver LDL

Small, dense LDL

Miller M, et al. Circulation. 2011;123:2292-2333 ISIS-APOCIIIRx Design

11 Chimeric RNase H ASO Design RNase H Terminating Mechanism ↑ affinity ↑ affinity ↑ stability RNase H Substrate ↑ stability ↑ tolerability ↑ tolerability

MOE DNA MOE

Clinical Experience with 2nd Generation ASOs  >4000 subjects treated by IV and/or SC administration  >100 clinical studies  Multiple therapeutic indications  >100 patients dosed for >1 year  Some patients dosed for > 4 years Doses as high as 1200 mg tolerated   Specific sequence not repeated throughout genome, reducing potential for off-target binding Phase 2 Open Label Cohort in FCS

12

 Three patients in ApoCIIIRx Study in FCS  Homozygotes or compound heterozygote for FCS-causing null LPL gene mutations

 Have LPL mass but no or extremely low level (<5%) of LPL activity

Characteristic Patient 1 Patient 2* Patient 3* Gender Male Female Female Age, yrs 45 67 28 BMI, kg/m2 23.7 29.0 23.4 Genotype P207L/P207L P207L/G188E P207L/P207L *participated in post-heparin LPL activity measurements

Treatment Period Post-Treatment

300 mg ApoCIIIRx f/u Period Once a week for 13 Weeks

13 weeks R Screen

D1 D8 D15 D22 D29 D36 D43 D50 D57 D64 D71 D78 D85 ISIS-APOCIIIRx Treatment Reduced Fasting Plasma ApoC-III and Levels in FCS Patients

13 Fasting ApoC-III Levels Fasting Triglyceride Levels

Parameter Primary Change from % Change from (mg/dL) Patient No. Baseline* Endpoint† Baseline Baseline 1 1406 616.5 -789.5 -56.2 Triglyceride 2 2083 287.5 -1795.5 -86.2 3 2043 734.5 -1308.5 -64.0 1 18.9 5.5 -13.4 -70.9 ApoC-III 2 35.1 3.4 -31.7 -90.4 3 19.8 3.5 -16.3 -82.5 ISIS-APOCIIIRx Treatment Reduced Fasting Plasma Chylomicron-TG and ApoB-48 Levels in FCS Patients

14 Fasting Chylomicron-TG Levels Fasting ApoB-48 Levels

Parameter Primary Change from % Change from (mg/dL) Patient No. Baseline* Endpoint† Baseline Baseline 1 1054 447.0 -607.4 -57.6 Chylomicron-TG 2 1641 151.5 -1489.8 -90.8 3 1511 622.4 -888.7 -58.8 1 0.98 0.83 -0.15 -14.8 ApoB-48 2 1.54 0.27 -1.27 -82.2 3 0.72 0.53 -0.19 -26.3 Non-HDL Cholesterol was also Reduced in Parallel with Triglyceride Levels

15 High Correlation Between ApoC-III and Triglycerides and Between Chylomicron-TG and Triglycerides

16 ISIS-APOCIIIRx Safety and Tolerability 17  Drug-related adverse events

 No elevations of liver enzymes >3x ULN

 No abnormalities in renal function

 No clinically meaningful changes in other laboratory values

 Tolerability  Generally well tolerated

 No flu-like symptoms

 Low incidence of injection site reactions (primarily mild erythema) Postulated extracellular effects of apoA-V on TG-rich metabolism.

Forte T M et al. J. Lipid Res. 2009;50:S150-S155

©2009 by American Society for Biochemistry and Molecular Biology Hereditary Defects in apoA-V Cause HTG 19

. Impaired synthesis of apoA-V (1131T>C variant) linked to HTG in 25% of patients . 50K participants in 27 studies

APOA1/C3/A4/A5 “gene cluster” & dyslipidemia

Sarwar et al.,, Lancet 2010 APOA5 Causal for both Hypertriglyceridemia and Premature Cardiovascular Disease

APOA5 Association with Lipid APOA5 Association in Patients levels in Patients with HTG with Coronary Heart Disease

50K participants in 27 studies 21K cases, 35K controls in 39 studies 20 Apo-A5 has a High Impact at Low Concentrations

• Attractive template for anti-HTG peptidomimetics • Apo-A5 physiologically active at low concentrations

Apolipoprotein Effect on TG levels Plasma concentration apoC-III  3.4 μM apoC-II  34.7 μM apoA-V  0.0038 μM

. Apo-a5 knockout mice have 4x higher TG (Science, 2001) . Apo-A5 gene expression lowers TG in normal mice by ~ 66% . Plasma concentration is 10,000-fold less than apo-C2 or Apo-AI

21 Technology: AV-peptide to Stimulate Lipase Activity 22

. AV-peptides binds to VLDL, lipase & heparan . lead-peptide (AV-H/K) can sulfate (acts as a “reservoir”) boosts lipase activity 8x ( )

2D Graph 4 Rate of TG Hydrolysis LDL, VLDL & 4 VLDL

) AV199-232

4 C-II AV201-232 A-V 3 AV205-232 TG AV-peptide AV-H/K B48, 100 C-III 2

LpL 1 heparan sulfate x 10 (RFU activity LpL Cells, tissues proteoglycan 0 FA 0 2 4 6 8 10 12 14 16 Time (min) Apo-CII Peptidomimetic Structure

• Apo-C2 peptidomimetic is 2 alpha helices joined together – 36 aa

• Helix1 is a high affinity peptide for - previously described, 18A

• Helix2 derived from apo-CII LPL activating domain

• More effective than full length Apo C2

• Increased ABCA1 cholesterol efflux 23 Effective in both Apo-C2 Deficient and General HTG Patients

• Addition of Apo-C2 ex vivo was highly efficacious in Apo-C2 deficient patients • Was also efficacious in HTG population – over 50 subjects tested • Data suggest an enhanced efficacy in the presence of LPL 24 Apo-C2 modulates TG and Cholesterol Levels in Apo-E Knockout Mice

Time (h) Time (h) • Apo-E Knockout mice were given Apo-C2 bolus and followed for 4 hours • Consistent with in vitro activities, there was a decrease in both TG and Cholesterol

25 DGAT Catalyzes TG Synthesis

R.V. Farese Jr. et al. COL 2000 Role of Acyl CoA: diacylglycerol acyltransferase 1 (DGAT1) in the Absorption of Fat

 DGAT1 catalyzes final step in triglyceride synthesis

 DGAT1 is expressed in gut > adipose, liver, skeletal muscle, heart 27 Inhibition of DGAT2 Decreases Hepatic Triglyceride (TG) Accretion and Secretion

Intracellular TG Secreted TG

4 hrs with 0.4 mM [3H]oleate

Li et al, ATVB 2015 DGAT Inhibition as a Treatment for Obesity

• Pharmaceutical companies have DGAT inhibitor programs • Some data from clinical trials with DGAT1 inhibitor are available but it does not look all that good: diarrhea • Why so different from mice?: • A rare DGAT1 mutation in human is associated with congenital diarrheal disorder (very severe): kids die within 6 months

• DGAT2 inhibitor has been developed

Harris et al. JCI 2012 FXR Agonism for Hypertriglyeridemia and NASH

Biliary and fecal cholesterol

ABCG5/8 LPL VLDL TG Ch IDL VLDLr LDLr LDL

CES/CEH CETP SR-B1 PLTP LDLox

HDL ABCA1

SR-B1

• HDL declines reflect upregulation of reverse cholesterol transport Macrophage • TG declines from SREBP-1c downregulation • LDL increase from CETP block? Increased LPL activity? 30 Improvement in NAS components

Steatosis Inflammation Ballooning

p = 0.001 p = 0.006 p = 0.03 60% 60% 60% 50% 50% 50% 40% 40% 40% 30% 30% 30% improved 20% 38% 61% 20% 35% 53% 20% 31% 46%

10% 10% 10% Percent subjects of Percent 0% 0% 0% Placebo OCA Placebo OCA Placebo OCA

1,0 p = 0.0004 1,0 p = 0.0006 1,0 p = 0.03 0,6 0,6 0,6 0,2 -0.4 -0.8 0,2 -0.2 -0.5 0,2 -0.2 -0.5 -0,2 -0,2 -0,2 -0,6 -0,6 -0,6 Change score in Change -1,0 -1,0 -1,0 Placebo OCA Placebo OCA Placebo OCA

Neuschwander-Tetri et al, The Lancet, http://dx.doi.org/10.1016/S0140-6736(14)61933-4 Serum

Neuschwander-Tetri et al, The Lancet, http://dx.doi.org/10.1016/S0140-6736(14)61933-4 A Treasure Trove of Information for Lipoprotein Biology

Dietary fat, cholesterol Liver Bile salts, cholesterol GCKR MLXILP B48 LDLR E CYP7A Lipogenesis MEV-MMAB PNLIP ABCG5 C HMGCR CEL ABCG8 LRP1 NPC1L1 Remnant SCABR1 Cholesterol LDLR LPA Intestine Lipolysis B100 Phospholipid Protein Cholesteryl B100 ester (CE) (PL) B48 E Triglycerides C A I (TG) LP (a) VLDL B100 B100 A I All A I A V TG Nascent E CE LIPC A IV LCAT HDL CETP E LDL Chylomicron HDL PLTP IDL Fatty Cholesterol, Fatty Lipolysis acids PL Lipolysis acids LPL

LPL CD36 ABCA 1 LIPG CD36 LDLR ABCG1 PCSK9 Inhibition transporters Glycosylation ANGPTL3 GALNT2 CELSR2-PCRC1-SORT1 Degradation TRIB1 Peripheral tissues NCAN-CLIP2-PBX4 Adapted from Lusis AJ, et al. Nat Genet. 2008;40:129-130. Omics and Emerging TG-Lowering Therapies

Potential targets for gene replacement therapy: LPL, apoC2, ApoA-5, GPIHBP1

Potential targets for anti-sense therapy: apoB, apoC-III, DGAT2, MicroRNAs Aptamers

Cell Pathways: Peptide linker technologies

metabolic pathways: DGAT-2inh, MTPI, FXR agonism

Peptide-based mimetics: ApoC2, apoE, ApoC5 Monoclonal Ab-ANGLPT 3